Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson acquired 9,391 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were bought at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the purchase, the chief financial officer directly owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This represents a 53.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Sensei Biotherapeutics Stock Performance
FTH opened at $22.87 on Friday. The stock has a market capitalization of $30.69 million, a PE ratio of -0.16 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a twelve month low of $6.32 and a twelve month high of $36.76.
Analysts Set New Price Targets
Several equities analysts have issued reports on the company. HC Wainwright started coverage on Sensei Biotherapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price objective for the company. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a report on Friday. They set an “outperform” rating and a $57.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $58.50.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
